Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | GCK | P35557 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3167048 | 0.73 | NFE2L2 (0.45) | PDE2AGCKNFE2L2MAPK14 | |
| SCHEMBL12676300 | 0.72 | MAPT (0.41) | MAPTNFE2L2KDM1AMAOAMAOB | |
| SCHEMBL13096994 | 0.72 | CHRNB4 (0.48) | — | |
| SCHEMBL14785178 | 0.71 | NPSR1 (0.46) | KDM4ETSHRALDH1A1 | |
| SCHEMBL14785228 | 0.71 | KMT2A (0.47) | KDM4ETSHRALDH1A1 | |
| SCHEMBL14785190 | 0.71 | MAPT (0.48) | MAPTKDM4ETSHRALDH1A1 | |
| SCHEMBL3099087 | 0.71 | LNPEP (0.40) | PDE2AGCKNFE2L2MAPK14 | |
| SCHEMBL13107095 | 0.71 | ALDH1A1 (0.48) | PDE2ACHRM2CHRM1KDM4ETSHR | |
| SCHEMBL22544861 | 0.71 | MMP12 (0.45) | GCKNFE2L2CHRM2CHRM1CHRM3 | |
| SCHEMBL13097262 | 0.71 | CHRNB4 (0.46) | PDE2AGCKNFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130921-A1 | TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORS | AcuraStem Incorporated (US) | 2026-05-14 | — | — | US | disclosed |
| US-20240352026-A1 | PIKFYVE KINASE INHIBITORS | AcuraStem Incorporated | 2024-10-24 | — | — | US | disclosed |
| US-20240197747-A1 | TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORS | AcuraStem, Inc. (US) | 2024-06-20 | — | — | US | disclosed |
| US-20230135152-A1 | PIKFYVE KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-04 | — | — | US | disclosed |
| EP-4103281-A1 | PIKFYVE KINASE INHIBITORS | Acurastem Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20210338683-A1 | TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-11-04 | — | — | US | disclosed |
| WO-2021163727-A1 | PIKFYVE KINASE INHIBITORS | AcuraStem Incorporated (US) | 2021-08-19 | — | — | WO | disclosed |
| EP-3676264-A1 | PIKFYVE KINASE INHIBITORS | Acurastem Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| US-20200199136-A1 | PIKFYVE KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-06-25 | — | — | US | disclosed |
| WO-2019046316-A1 | PIKFYVE KINASE INHIBITORS | ACURASTEM INC. (US) | 2019-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135152-A1 | PIKFYVE KINASE INHIBITORS | PIKFYVE, PIP5K1B, PIP5K1C | MAPT 1501/4885PDE2A 1782/4885GCK 937/4885 |
| US-20200199136-A1 | PIKFYVE KINASE INHIBITORS | PIKFYVE, PIP5K1B, PIK3CA | MAPT 1959/4885PDE2A 1489/4885GCK 891/4885 |
| US-20240352026-A1 | PIKFYVE KINASE INHIBITORS | PIKFYVE, PIP5K1B, PIK3CA | MAPT 1959/4885PDE2A 1489/4885GCK 891/4885 |
| US-20240197747-A1 | TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORS | PIKFYVE, TMPRSS2, TMPRSS4 | MAPT 2796/4885PDE2A 2600/4885GCK 1675/4885 |
| US-20260130921-A1 | TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORS | TMPRSS2, TMPRSS11D, TMPRSS6 | MAPT 2715/4885PDE2A 739/4885GCK 2257/4885 |
| US-20210338683-A1 | TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORS | PIKFYVE, TMPRSS2, TMPRSS4 | MAPT 2796/4885PDE2A 2600/4885GCK 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.